Investor Presentaiton
BIOND
BIOLOGICS
Soluble CD28 protein in plasma (pg/mL)
CD28 shedding is a novel immune regulatory
pathway in cancer patients
The BION-206 program
is based on novel
Biond discoveries:
Aberrant levels of
soluble CD28 were found in
cancer patients' plasma (WO
2019/175885)
The CD28 receptor was
found to be cleaved from
activated T cells by
cancer related MMP's
(PCT/IL2020/051243)
Soluble CD28
promotes an
immuno-suppressive
environment
50000
100000
• Above 1 μg/ml
NR
Melanoma
Pancreas
Head & Neck
Lung
Bladder
Breast
Colorectal
Gastric
Ovarian
Kidney
Sarcoma
.
11 tumor types were surveyed
15% of samples of studied tumors plasma
contain a higher level of soluble CD28
compared to plasma from healthy subjects
MMP, matrix metalloproteinases
Biond Biologics Corporate Presentation | May 2021 | Non-confidential
18
涯View entire presentation